Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Formaldehyde→

Formaldehyde Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50-00-0
Molecular formula
CH2O
Molecular weight
30.026 g/mol
Drug class
Reactive aldehydetopical chemical cauterant and fixative/disinfectant
Mechanism of action
Cross-links proteins and nucleic acids through covalent reactions with amino and other functional groups, causing tissue fixation and microbial inactivation. This reactivity also underlies toxicity and sensitisation risk.
Indications / reported uses
  • Historical or limited topical use for treatment of plantar warts or hyperhidrosis in selected products; formaldehyde is also used as a disinfectant and tissue fixative, which are not therapeutic API indications. Use is restricted by irritation and sensitisation concerns.

Sources: NLM MeSH — Formaldehyde · PubChem — Formaldehyde · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Formaldehyde Environmental Risk Assessment (ERA) (the Formaldehyde ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.